REG - IXICO plc - Strategic Data Partnership with GAP

IXICOAnnouncement

Tue 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250722:nRSV9260Ra&default-theme=true

RNS Number : 9260R  IXICO plc  22 July 2025

IXICO plc

("IXICO", the "Company" or the "Group")

 

Strategic Partnership between IXICO and the Global Alzheimer's Platform
Foundation (GAP)

 

Agreement provides full data rights to the Bio-Hermes-002 Study in Alzheimer's
Disease (AD)

 

Deepens IXICO's platform capability and involvement in global AD consortium

 

 

22 July 2025 IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in
neuroscience imaging and biomarker analytics, using its AI-driven platform to
help advance drug development in neurological disorders, today announced it
has deepened its existing collaboration with the Global Alzheimer's Platform
Foundation® (GAP) through an agreement securing full data usage rights in
GAP's landmark Bio-Hermes-002 study.

 

GAP's Bio-Hermes-002 is one of the most prominent global studies in AD
research, which aims to enhance the understanding of newly identified AD
biomarkers and advance the regulatory acceptance of those biomarkers for use
in clinical trials. IXICO is working closely with GAP and other
biopharmaceutical companies engaged in Bio-Hermes-002, using its unique
AI-driven platform and expertise, to assist with the neuroimaging analysis of
the Bio-Hermes-002 study data. IXICO's participation in the trial further
establishes it as a consortium partner of leading biopharmaceutical players
jointly combatting AD.

 

Under the agreement, IXICO will pay GAP in a combination of cash and analysis
services to GAP for the data usage rights.  The board expects a strong return
on this investment, as data from Bio-Hermes-002 will enable IXICO to:

·     directly accelerate its market differentiating vascular biomarker
analysis R&D program in AD and adjacent neurodegenerative diseases;

·     extend its product offering to support blood-based biomarker market
approval and use in AD; and

·     deepen its relationship with GAP and engage directly with leading
biopharmaceutical companies in the AD space.

 

Bram Goorden, CEO of IXICO, commented: "This official partnership strengthens
the deep collaboration between IXICO and GAP.  Working with GAP and the
consortia partners is very rewarding clinically, and it is also particularly
important for two strategic reasons. Firstly, it confirms IXICO's leading role
in the AD research ecosystem, a key element in driving continued commercial
opportunities. Secondly, the unique study data enables us to further develop
highly differentiated neuroimaging biomarker technologies that advance the
understanding, diagnosis and treatment for patients suffering from AD."

 

John Dwyer, President and CEO of GAP, commented: "GAP is proud to partner
again with IXICO on the Bio-Hermes-002 study.  Together, we're working to
advance clinical trial design for Alzheimer's and related dementias by using
cutting-edge technology to better detect disease pathology.  IXICO's
expertise brings valuable precision to this global effort at a critical time
for the field."

 

Ends

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the UK version of the EU
Market Abuse Regulation 596/2014 which is part of UK law by virtue of the
European Union (Withdrawal) Act 2018, as amended and supplemented from time to
time. Upon the publication of this announcement, this inside information is
now considered to be in the public domain.

 

For further information please contact:

 IXICO plc                                   +44 (0) 20 3763 7499
 Grant Nash, Chief Financial Officer

 James Chandler, Chief Business Officer

 Cavendish Capital Markets Limited           +44 (0) 20 7220 0500

 (Nominated Adviser and Sole Broker)
 Giles Balleny (Corporate Finance)

 Nigel Birks (Healthcare Specialist Sales)

 Harriet Ward (Corporate Broking)

 Michael F Johnson (Sales)

 

 

About the Bio-Hermes-002 study:

The Bio-Hermes-002 study is the second blood-based and digital biomarker
study in partnership with the Global Alzheimer's Platform Foundation®.
 Bio-Hermes-002 (https://globalalzplatform.org/biohermes-002study/)  builds
on the success of  Bio-Hermes-001
(https://globalalzplatform.org/biohermesstudy/) , the first-of-its-kind study
comparing blood-based biomarkers, digital cognitive tests, retinal exams, and
speech analytics to traditional methods of measuring cognition including
beta-amyloid positron emission tomography (PET) scans, the gold standard for
measuring Alzheimer's disease (AD) pathology. The research study seeks
volunteers with or without memory concerns to help identify new blood or
digital tests that can help predict the presence of amyloid plaques and
neurofibrillary tangles in the brain, which are the hallmarks of Alzheimer's
disease.

 

About the Global Alzheimer's Platform Foundation (GAP)
www.globalalzplatform.org (http://www.globalalzplatform.org)

The nonprofit Global Alzheimer's Platform Foundation was founded to speed the
delivery of Alzheimer's treatments with a commitment to lowering the cost and
improving the efficacy of ADRD clinical trials to ensure that treatments and
therapies work for everyone. As part of its mission, GAP supports more than
100 clinical research sites worldwide through study start-up and recruitment
activities, promoting inclusivity in research studies, and celebrating the
citizen scientists who make research possible.

 

About IXICO www.IXICO.com (http://www.IXICO.com)

IXICO is a global leader in neuroscience imaging and biomarker analytics,
using its proprietary AI-driven platform to help advance the treatment of
neurological disorders and reduce the uncertainties associated with drug
discovery, development and monitoring.   As a key part of the global
neurological disease research community, the Company has built a global
reputation and 20-year track record as an end-to-end Imaging Contract Research
Organisation (iCRO) working with leading pharma companies, innovative
biotech's, disease consortia and non-profit organisations. IXICO has supported
hundreds of neurological clinical trials, analysed hundreds of thousands scans
and built an expansive network of expert imaging centres around the world.

 

The IXICO Platform is tailor-made for neurological disease, reliably
processing data from global trials, precisely measuring key imaging biomarkers
associated with the identification, progression and treatment of diseases such
as Alzheimer's, Huntington's and Parkinson's.  Image data is interrogated by
the Platform and IXICO's expert scientists translating complex data into
clinically meaningful while minimizing data variability and increasing
reproducibility.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRZFLFLEDLEBBX